深部靜脈血栓症(DVT)市場:現狀分析與預測(2024-2032年)

深部靜脈栓塞 (DVT) 市場預計將呈現約 8% 的成長率。這主要是由於外科手術尤其是骨科手術的增加，增加了對DVT預防和治療的需求。此外，影像和診斷工具的進步以及 DVT 治療研發投資的增加將進一步支持市場成長。例如，2021年，醫療器材巨頭波士頓科學公司宣布以高達12億美元的價格收購行動心臟健康解決方案和遠端監控服務開發商Preventice Solutions, Inc.。

依藥物類別，市場分為抗凝血劑、肝素等。抗凝血劑預計將佔據深部靜脈栓塞 (DVT) 市場的最大佔有率，因為它們為 DVT 的急性治療和長期管理提供了重要的治療選擇。 DOAC 將 DVT 治療與華法林等傳統藥物分開，使其更安全、更方便。較新的護理點口服抗凝血劑，如阿?沙班、利伐沙班、達比加群和依度沙班，具有某些特點，使其在起效快、藥物動力學更好以及相對較少的飲食限制和監測方面優於華法林。因此，由於患者依從性的提高和治療結果的改善，市場規模不斷擴大。此外，該類別中正在進行的現有研究和創新旨在提高療效、安全措施和患者依從性，因為此類治療正在全球市場上擴展，以支持 DVT 市場的成長。

根據治療，市場分為手術、藥物和其他。其中，由於藥物治療的進步，特別是抗凝血劑華法林和直接口服抗凝血劑等藥物類型，預計藥物將佔據深部靜脈栓塞（DVT）市場的最大佔有率。隨著目前研究的目標是開發不僅更安全而且更有效的抗凝血劑，市場也在不斷增長。生物相似藥和仿製藥的可用性也使得這些治療方案變得負擔得起且容易獲得。此外，包括大手術在內的高風險患者的預防性用藥將增加對該類藥物的需求，從而刺激全球市場的成長。

根據最終用戶，市場分為醫院、專科診所、學術/CRO 等。其中，醫院類別預計在預測期內將引領深部靜脈栓塞（DVT）市場佔有率。初級保健中心和醫院通常是出現 DVT 症狀的患者的第一個接觸點。在醫院引入先進的診斷工具和影像技術有助於早期、準確的診斷，這對於有效管理和改善病患治療效果至關重要。此外，醫院是實施預防措施的核心，特別是對於接受手術或長時間臥床不起的患者，對 DVT 的預防和管理做出了重大貢獻。

為了更了解深部靜脈栓塞（DVT）治療的市場介紹，市場為北美（美國、加拿大和其他北美地區）、歐洲（德國、英國、法國、西班牙、義大利和其他歐洲地區），根據亞太地區（中國、日本、印度、亞太地區其他地區）和世界其他地區的全球影響力進行分析。北美深部靜脈血栓 (DVT) 市場環境在醫療設施、意識和強大的研發方面非常先進。該地區肥胖、久坐生活方式和人口老化等風險發生率較高，因此患者群體龐大，產生了整體業務。診斷開發包括改進影像技術和識別新的生物標記物，有助於更好的診斷和更有效的治療。此外，專注於新治療方法（例如新型口服抗凝血劑和微創手術）的強大策略參與者的市場進入進一步推動了市場向前發展。政府加強對醫療保健的支持以及如何預防和管理 DVT 的患者教育也在決定北美 DVT 市場方面發揮著重要作用。

市場上營運的主要公司包括：Medtronic、Aspen Holdings、Novartis AG、Mylan NV、GLENMARK PHARMACEUTICALS LTD.、Hikma Pharmaceuticals PLC、Bristol-Myers Squibb Company、GL Pharma、COBAPHARMA、Boehringer Ingelheim International GmbH等。

目錄

第1章 市場簡介

• 市場定義
• 主要目的
• 相關利益者
• 限制事項

第2章 調查手法或前提條件

• 調查流程
• 調查手法
• 受訪者簡介

第3章 摘要整理

• 產業摘要
• 各市場區隔預測
  • 市場成長的強度
• 地區展望

第4章 市場動態

• 促進因素
• 機會
• 阻礙因素
• 趨勢
• PESTEL分析
• 需求面分析
• 供給面分析
  • 合併和收購
  • 投資情勢
  • 產業洞察：主要新創公司及其獨特策略

第5章 價格分析

• 各地區價格分析
• 價格的影響因素

第6章 全球深部靜脈血栓症(DVT)市場收益，2022-2032F年

第7章 各類藥物的市場分析

• 抗凝血藥
• 肝素
• 其他

第8章 不同治療的市場分析

• 手術
• 藥物
• 其他

第9章 各終端用戶的市場分析

• 醫院
• 專門診所
• 學術·CRO
• 其他

第10章 各地區的市場分析

• 北美
  • 美國
  • 加拿大
  • 其他北美地區
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 全球其他地區

第11章 價值鏈分析

• 限制分析
• 市場參與企業一覽

第12章 競爭情形

• 競爭儀表板
• 競爭市場定位分析
• 波特的五力分析

第13章 企業簡介

• Medtronic
• Aspen Holdings
• Novartis AG
• Mylan N.V.
• GLENMARK PHARMACEUTICALS LTD.
• Hikma Pharmaceuticals PLC
• Bristol-Myers Squibb Company
• GL Pharma
• COBAPHARMA
• Boehringer Ingelheim International GmbH

第14章 縮寫與前提條件

第15章 附錄

The global deep vein thrombosis (DVT) market relates to the diagnosis, therapy, and prevention of blood clots located in deep veins predominantly in lower limbs, which if left unattended may cause a life-threatening disease known as pulmonary embolism. The market is therefore motivated by these factors including increasing incidences of DVT especially among the aging populace, rising awareness of the condition, improvement in diagnostic tools and treatment options, and increasing risk factors which include obesity, less active lifestyles, and other conditions that are known to cause the condition. Also, the increasing number of healthcare facilities across emerging nations and the incorporation of the latest anticoagulant drugs sustain market growth. Currently, healthcare organizations are striving to address DVT to lessen the risk of adversative events within the global market, enhancement, especially in research and development to benefit patients.

The market for deep vein thrombosis market is set to exhibit a growth rate of about 8%. This is mainly due to the rise in surgical procedures, especially orthopedic surgeries, which increases the need for DVT prophylaxis and treatment. Also, advancements in imaging and diagnostic tools and growing investment in R&D for the treatment of DVT will further boost the market growth. For instance, in 2021, Boston Scientific, a leading medical device company, announced it would acquire Preventice Solutions, Inc., a mobile cardiac health solutions developer, and remote monitoring services, for up to USD 1.2 billion.

Based on the drug class, the market is segmented into anticoagulants, heparin, and others. The anticoagulants category is expected to have the largest market share of the deep vein thrombosis market by offering essential therapeutic options for both acute treatment and long-term management of DVT. DOACs have removed DVT treatment from traditional therapeutics such as warfarin and made it safer and more convenient. New point-of-care oral anticoagulants, including apixaban, rivaroxaban, dabigatran, and edoxaban have certain characteristics and are distinguished from warfarin by a quick onset of action, more favorable pharmacokinetics, limited restrictions in terms of diet and relatively low requirements in terms of monitoring. It has as a result enhanced patient compliance and improved results and therefore the market size has spread. Further, the existing research and innovation conducted in this category are aimed at increasing the effectiveness, safety measures, and patient compliance to fuel the growth of the DVT market as such therapies spread all over the global market.

Based on the treatment, the market is segmented into surgery, drugs, and others. Among these, the drugs category is expected to have the largest market share of the deep vein thrombosis market due to the progression in pharmaceutical care, especially among some types of drugs, such as anticoagulants warfarin and direct oral anticoagulants. The market is also growing constantly because current research has been directed at creating not only safer but also more effective anticoagulants. Also, biosimilar, and generic availability contribute to the affordability and accessibility of these treatment programs. Also, preventive medication for high-risk patients, including the major surgery ones, boosts demand for this medication type, and, thus, will stimulate global market growth.

Based on the end-user, the market is segmented into hospitals, specialty clinics, academic & CROs, and others. Among these, the hospital category is expected to lead the market share of the deep vein thrombosis market during the forecast period. Primary care centers and hospitals are often the first point of contact for patients presenting with DVT symptoms. The adoption of advanced diagnostic tools and imaging technologies in hospitals facilitates early and accurate diagnosis, which is crucial for effective management and improved patient outcomes. Moreover, hospitals are central to implementing prophylactic measures, especially for patients undergoing surgeries or those with prolonged immobility, significantly contributing to the prevention and management of DVT.

For a better understanding of the market adoption of deep vein thrombosis treatment, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The market environment of North America Deep Vein Thrombosis (DVT) is highly advanced in terms of healthcare facilities, awareness, and strong R&D. The incidence of risks like obesity, sedentary lifestyle, and aging population across the region presents a large patient pool for generating overall business. The diagnostic development includes the improvement of imaging techniques and the identification of new biomarkers which contribute to better diagnosis and powerful treatment. Additionally, the market entry of strong strategic players focusing on new therapeutic approaches, including novel oral anticoagulants and less invasive procedures, advances the market further. Increased government support for the coverage of healthcare and the education of patients on how to prevent and manage DVT are other prominent roles that help in the determination of the North American market for DVT.

Some of the major players operating in the market include Medtronic, Aspen Holdings, Novartis AG, Mylan N.V., GLENMARK PHARMACEUTICALS LTD., Hikma Pharmaceuticals PLC, Bristol-Myers Squibb Company, GL Pharma, COBAPHARMA, Boehringer Ingelheim International GmbH.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Global Deep Vein Thrombosis Market
• 2.2. Research Methodology of the Global Deep Vein Thrombosis Market
• 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

• 3.1. Industry Synopsis
• 3.2. Segmental Outlook
  • 3.2.1. Market Growth Intensity
• 3.3. Regional Outlook

4.MARKET DYNAMICS

• 4.1. Drivers
• 4.2. Opportunity
• 4.3. Restraints
• 4.4. Trends
• 4.5. PESTEL Analysis
• 4.6. Demand Side Analysis
• 4.7. Supply Side Analysis
  • 4.7.1. Merger & Acquisition
  • 4.7.2. Investment Scenario
  • 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.PRICING ANALYSIS

• 5.1. Regional Pricing Analysis
• 5.2. Price Influencing Factors

6.GLOBAL DEEP VEIN THROMBOSIS MARKET REVENUE (USD MN), 2022-2032F

7.MARKET INSIGHTS BY DRUGS CLASS

• 7.1. Anticoagulants
• 7.2. Heparin
• 7.3. Others

8.MARKET INSIGHTS BY TREATMENT

• 8.1. Surgery
• 8.2. Drugs
• 8.3. Others

9.MARKET INSIGHTS BY END-USER

• 9.1. Hospitals
• 9.2. Specialty Clinics
• 9.3. Academic & CROs
• 9.4. Others

10.MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11.VALUE CHAIN ANALYSIS

• 11.1. Marginal Analysis
• 11.2. List of Market Participants

12.COMPETITIVE LANDSCAPE

• 12.1. Competition Dashboard
• 12.2. Competitor Market Positioning Analysis
• 12.3. Porter Five Forces Analysis

13.COMPANY PROFILED

• 13.1. Medtronic
  • 13.1.1. Company Overview
  • 13.1.2. Key Financials
  • 13.1.3. SWOT Analysis
  • 13.1.4. Product Portfolio
  • 13.1.5. Recent Developments
• 13.2. Aspen Holdings
• 13.3. Novartis AG
• 13.4. Mylan N.V.
• 13.5. GLENMARK PHARMACEUTICALS LTD.
• 13.6. Hikma Pharmaceuticals PLC
• 13.7. Bristol-Myers Squibb Company
• 13.8. GL Pharma
• 13.9. COBAPHARMA
• 13.10. Boehringer Ingelheim International GmbH

14.ACRONYMS & ASSUMPTION

15.ANNEXURE